Published in Pharma Law Weekly, January 9th, 2007
"Patients are too often treated only with OADs long after insulin therapy should have been initiated, resulting in poor glycaemic control and an increased risk of serious, long-term complications," said lead investigator Phillip Raskin, M.D., professor, University of Texas, Southwestern Medical Center. "In fact, our study showed that no patient with an HbA1c level...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.